1Leenen CHM & Dieleman LA (2007) Inulin and oligofructose in chronic inflammatory bowel disease. J Nutr 137, 2572S–2575S.
2Loftus EV Jr & Sandborn WJ (2002) Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 31, 1–20.
3Bernstein CN, Blanchard JF, Kliewer E, et al. (2001) Cancer risk in patients with inflammatory bowel disease. Cancer 48, 526–535.
4Hendrickson BA, Gokhale R & Cho JH (2002) Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 15, 79–94.
5Wasser SP (2002) Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60, 258–274.
6Sullivan R, Smith JE & Rowan NJ (2006) Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 49, 159–170.
7Williams DL, Mueller A & Browder W (1996) Glucan-based macrophage stimulators: a review of their anti-infective potential. Clin Immunother 5, 392–399.
8Wu DY, Han SN, Bronson RT, et al. (1998) Dietary supplementation with mushroom-derived protein-bound glucan does not enhance immune function in young and old mice. J Nutr 128, 193–197.
9Williams DL & Browder IW (1994) Development of natural product (1 → 3)-β-d-glucan polymers as immune-stimulating pharmaceuticals. Polymers Adv Technol 5, 529–534.
10Rice PJ, Adams EL, Ozment-Skelton T, et al. (2005) Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther 314, 1079–1086.
11Lavi I, Friesem D, Geresh S, et al. (2006) An aqueous polysaccharide extract from the edible mushroom Pleurotus ostreatus induces anti-proliferative and pro-apoptotic effects on HT-29 colon cancer cells. Cancer Lett 244, 61–70.
12Tao Y, Zhang L & Cheung PC (2006) Physicochemical properties and antitumor activities of water-soluble native and sulfated hyperbranched mushroom polysaccharides. Carbohydr Res 341, 2261–2269.
13Bobek P & Galbavy S (2001) Effect of pleuran (β-glucan from Pleurotus ostreatus) on the antioxidant status of the organism and on dimethylhydrazine-induced precancerous lesions in rat colon. Br J Biomed Sci 58, 164–168.
14Nosalova V, Bobek P, Černa S, et al. (2001) Effects of pleuran (β-glucan isolated from Pleurotus ostreatus) on experimental colitis in rats. Physiol Res 50, 575–581.
15Vetvicka V, Thorton BP & Ross GD (1996) Soluble β glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonised target cells. J Clin Invest 98, 50–61.
16Thorton BP, Vetvicka V & Pitman M (1996) Analysis of the sugar specificity and molecular location of the β-glucan binding site of complement receptor type 3 (CD11b/CD18). J Immunol 156, 1232–1245.
17Ardon O, Kerem Z & Hadar Y (1998) Enhancement of lignin degradation and laccase activity in Pleurotus ostreatus by cotton stalk extract. Can J Microbiol 44, 676–680.
18Kodama N, Yamada M & Nanba H (2001) Addition of Maitake D-fraction reduces the effective dosage of vancomycin for the treatment of Listeria-infected mice. Jpn J Pharmacol 87, 327–332.
19Cooper HS, Murthy SN, Shah RS, et al. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69, 238–249.
20Loher F, Bauer C, Landauer N, et al. (2004) The interleukin-1β-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T-helper 1 T-cell activation. J Pharmacol Exp Ther 308, 583–590.
21Krawisz JE, Sharon P & Stenson WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87, 1344–1350.
22Dieleman LA, Palmen MJ, Akol H, et al. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114, 385–391.
23Rolandelli RH, Saul SH, Settle RG, et al. (1988) Comparison of parenteral nutrition and enteral feeding with pectin in experimental colitis in the rat. Am J Clin Nutr 47, 715–721.
24Lim BO, Lee SH, Park DK, et al. (2003) Effect of dietary pectin on the production of immunoglobulins and cytokines by mesenteric lymph node lymphocytes in mouse colitis induced with dextran sulfate sodium. Biosci Biotechnol Biochem 67, 1706–1712.
25Liu L, Wang ZP, Xu CT, et al. (2003) Effects of Rheum tanguticum polysaccharide on TNBS-induced colitis and CD4+T cells in rats. World J Gastroenterol 9, 2284–2288.
26Englyst HN, Quigley ME & Hudson GJ (1995) Definition and measurement of dietary fibre. Eur J Clin Nutr 49, Suppl. 3, S48–S62.
27Chung HL, Yue GG, To KF, et al. (2007) Effect of Scutellariae Radix extract on experimental dextran-sulfate sodium-induced colitis in rats. World J Gastroenterol 13, 5605–5611.
28Nusrat A, Parkos CA, Liang TW, et al. (1997) Neutrophil migration across model intestinal epithelia: monolayer disruption and subsequent events in epithelial repair. Gastroenterology 113, 1489–1500.
29Nakamura M, Saito H, Kasanuki J, et al. (1992) Cytokine production in patients with inflammatory bowel disease. Gut 33, 933–937.
30O'Shea J, Ma A & Lipsky P (2002) Cytokines and autoimmunity. Nature Rev 2, 37–45.
31Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nature Rev 3, 745–756.
32Pullman WE, Elsbury S, Kobayashi M, et al. (1992) Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 102, 529–537.
33Raab Y, Raab Y, Gerdin B, et al. (1993) Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut 34, 1203–1206.
34Nielsen OH, Brynskov J & Bendizen K (1993) Circulating and mucosal concentrations of tumor necrosis factor and inhibitor(s) in chronic inflammatory bowel disease. Dan Med Bull 40, 247–249.
35Akazawa A, Sakaida I, Higaki S, et al. (2002) Increased expression of tumor necrosis factor α messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol 37, 345–353.
36Olsen T, Goll R, Cui G, et al. (2007) Tissue levels of tumor necrosis factor-α correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol 42, 1312–1320.
37Järnerot G, Hertervig E, Friis-Liby I, et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128, 1805–1811.
38Rutgeerts P, Sandborn WJ, Feagan BG, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353, 2462–2476.
39Okada Y, Tsuzuki Y, Miyazaki J, et al. (2006) Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. Gut 55, 681–688.
40Hoentjen FZX, Tannock GW & Dieleman LA (2004) The prebiotic combination inulin and oligofructose prevents colitis in HLA-B27 transgenic rats. Can J Gastroenterol 18, Suppl. A, .
41McAlindon ME, Hawkey CJ & Mahida YR (1998) Expression of interleukin 1β and interleukin 1β converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 42, 214–219.
42Akira S, Hirano T, Taga T, et al. (1990) Biology of multi-functional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 4, 2860–2867.
43Rout D, Mondal S, Chakraborty I, et al. (2005) Chemical analysis of a new (1 → 3)-, (1 → 6)-branched glucan from an edible mushroom, Pleurotus florida. Carbohydr Res 340, 2533–2539.
44Wang JC, Hu SH, Liang ZC, et al. (2005) Optimization for the production of water-soluble polysaccharide from Pleurotus citrinopileatus in submerged culture and its antitumor effect. Appl Microbiol Biotechnol 67, 759–766.
45Melgar S, Yeung MM, Bas A, et al. (2003) Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol 134, 127–137.
46Asseman C, Mauze S, Leach MW, et al. (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190, 995–1003.
47Fiorentino DF, Zlotnik A, Vieira P, et al. (1991) IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146, 3444–3451.
48Fiorentino DF, Zlotnik A, Mosmann TR, et al. (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147, 3815–3822.
49Wogensen L, Huang X & Sarvetnick N (1993) Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin-10 in the islets of Langerhans. J Exp Med 178, 175–185.
50Balasa B & Sarvetnick N (1996) The paradoxical effects of interleukin 10 in the immunoregulation of autoimmune diabetes. J Autoimmun 9, 283–286.
51Furukawa Y, Becker G, Stinn JL, et al. (1999) Interleukin-10 (IL-10) augments allograft arterial disease. Paradoxical effects of IL-10 in vivo. Am J Pathol 155, 1929–1939.
52Roller M, Rechkemmer G & Watzl B (2004) Prebiotic inulin enriched with oligofructose combination with probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune function in rats. J Nutr 134, 153–156.
53Neissner M & Volk BA (1995) Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RTPCR). Clin Exp Immunol 101, 428–435.
54Kucharzik T, Stoll R & Lügering N (1995) Circulating anti-inflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 100, 452–456.